A clinical study on WT1-mutated AML refractory to induction chemotherapy suggested the use of vitamin C as adjunct therapy, based on the evidence that WT1 mutant leukemia cells show low 5hmC levels that in turn indicate reduced TET2 activity [15]. The gene discussed is TET2; the disease is leukemia.